PATH vs PGEN · P/E 19, rev $1.61B vs rev $1.8M
Uipath Inc (PATH) versus Precigen Inc (PGEN) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Precigen Inc (PGEN) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported PGEN revenue for 2023-06-30 was $1.8M. Net income was -$20.3M. Revenue was down 4.5% from 2023-03-31 to 2023-06-30. PGEN currently screens at market cap $419.2M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. PGEN currently screens at market cap $419.2M.
Not investment advice. Open the PATH and PGEN stock pages for the full models.
Not investment advice.